Related Experiment Videos
Neoral: a microemulsion cyclosporine
1College of Pharmacy, University of Iowa, Iowa City 52242, USA. david-min@uiowa.edu
Journal of Transplant Coordination : Official Publication of the North American Transplant Coordinators Organization (NATCO)
|March 1, 1996
Summary
Neoral, a new cyclosporine formulation, offers improved bioavailability and pharmacokinetics compared to Sandimmune. This enhances long-term transplant recipient stability by reducing drug level variability and associated risks.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Cyclosporine (Sandimmune) revolutionized transplant survival by reducing acute rejection.
- Maintaining stable immunosuppression requires precise cyclosporine blood levels, posing clinical challenges.
- Sandimmune exhibits low bioavailability and high pharmacokinetic variability, impacting patient outcomes.
Purpose of the Study:
- To evaluate Neoral, a novel microemulsion formulation of cyclosporine.
- To assess Neoral's impact on cyclosporine bioavailability and pharmacokinetics.
- To compare Neoral's clinical profile with the conventional Sandimmune formulation.
Main Methods:
- Clinical evaluation of Neoral (capsules and oral solution).
- Pharmacokinetic studies assessing bioavailability and variability.
- Safety profile comparison with Sandimmune.
Main Results:
- Neoral demonstrated improved cyclosporine bioavailability.
- Neoral significantly reduced inter- and intraindividual pharmacokinetic variability.
- Neoral's safety profile was comparable to Sandimmune.
Conclusions:
- Neoral offers enhanced pharmacokinetic properties for cyclosporine delivery.
- Improved bioavailability and reduced variability can lead to better long-term transplant stability.
- Neoral represents a significant advancement in managing immunosuppression for transplant recipients.